The company's lead product, VRS-317, is a recombinant growth hormone currently in a phase 2a clinical trial. Its value proposition is its longer half life versus current therapies. Injections are required once/month instead of daily.
The firm has yet to generate sales. Operations burned $17M last year.
Cash and equivalents at year end was $13.2M.